Sodium Selenite Increases the Activity of the Tumor Suppressor Protein, PTEN, in DU-145 Prostate Cancer Cells

Margareta Berggren
Department of Nutritional Sciences, College of Agriculture and Life Sciences, The University of Arizona, Tucson and Arizona Cancer Center, Tucson, Arizona, USA

Sivanandane Sittadjody
Department of Nutritional Sciences, College of Agriculture and Life Sciences, The University of Arizona, Tucson, Arizona, USA

Zuohe Song and Jean-Louis Samira
Department of Nutritional Sciences, College of Agriculture and Life Sciences, The University of Arizona, Tucson and Arizona Cancer Center, Tucson, Arizona, USA

Randy Burd
Department of Nutritional Sciences, College of Agriculture and Life Sciences, The University of Arizona, Tucson, Arizona, USA

Emmanuelle J. Meuillet
Department of Nutritional Sciences, College of Agriculture and Life Sciences, and the Department of Molecular and Cellular Biology, The University of Arizona, Tucson, Arizona Cancer Center, Tucson, Arizona, USA

INTRODUCTION

Epidemiological and clinical data suggest that selenium may prevent prostate cancer; however, the cellular effects of selenium in malignant prostate cells are not well understood. We previously reported that the activity of the tumor suppressor PTEN is modulated by thioredoxin (Trx) in a RedOx-dependent manner. In this study, we demonstrated that the activity of Trx reductase (TR) is increased by sevenfold in the human prostate cancer cell line, DU-145, after 5 days of sodium selenite (Se) treatment. The treatment of DU-145 cells with increasing concentrations of Se induced an increase in PTEN lipid phosphatase activity by twofold, which correlated with a decrease in phospho-ser473-Akt, and an increase in phospho-Ser370-PTEN levels. Se also increased casein kinase-2 (CK2) activity; and the use of apigenin, an inhibitor of CK2, revealed that the regulation of the tumor suppressor PTEN by Se may be achieved via both the Trx-TR system and the RedOx control of the kinase involved in the regulation of PTEN activity.

Submitted 25 January 2008; accepted in final form 3 September 2008.
Address correspondence to Emmanuelle J. Meuillet, The University of Arizona, Department of Nutritional Sciences, College of Agriculture and Life Sciences, 1177 East 4th Street, P.O. Box 210038, Tucson, AZ 85721-0038, Phone: 520-626-5794. Fax: (520) 626-4455. E-mail: emeuillet@azcc.arizona.edu
Trx is a physiological inhibitor of the tumor suppressor protein deleted on chromosome 10/mutated in multiple advanced cancer (PTEN/MMAC1 phosphatase and tensin homolog), the phosphatidylinositol (PtdIns)-3-phosphate phosphatase that regulates Akt activation in normal cells (14). In PTEN-deficient mouse embryo fibroblasts, constitutively elevated activity of Akt together with decreased sensitivity to apoptosis suggests a role for PTEN as a negative regulator of cell survival.

PTEN is a 54 kDa protein, which exhibits a dual specificity tyrosine/serine/threonine and lipid phosphatase, but the main substrate of PTEN, both in vitro and in living cells, is the lipid PtdIns-(3,4,5)-trisphosphate. PTEN is also a phosphoprotein, and this posttranscriptional modification of the protein plays an important role in its stability (16). Specifically, the phosphorylation of Ser380 and Thr382 has been shown to affect the half-life of PTEN in T lymphocytes (17). Thus, PTEN is phosphorylated at several serine and threonine residues in the C-terminal of the protein, particularly in the PDZ (PSD95,Dlg and ZO1)-binding motif. Interestingly, the phosphorylation of the PTEN tail results in an inhibition of PTEN activity, at least in part, by preventing its interaction with PDZ domain-containing proteins such as MAGI-2. Moreover, the phosphorylation on Thr566 by glycogen synthase kinase 3 (GSK3) was recently shown to destabilize PTEN (18). Taken together, PTEN activity may be regulated via its phosphorylation on the C-terminus and its association with PDZ binding partners.

The activation and the regulation of the kinases involved in PTEN phosphorylation and their effects on PTEN activity in prostate cancer cells remain an important topic to be investigated. Our laboratory is interested in understanding the possible mechanisms for PTEN regulation in normal and cancer cells. We have shown that the small RedOx protein, Trx, inhibits PTEN activity in MCF-7 breast cancer cells (14,15). Trx, by binding directly to the C-terminal part of PTEN, inhibits PTEN lipid phosphatase activity in vitro and in cells. The interaction between Trx and PTEN is dependent on the RedOx status of Trx in that the interaction is observed only under reducing conditions (14). Our observations strongly suggest that Trx regulates PTEN activity in the cells and that this interaction may partially clarify the antiapoptotic functions of Trx in the cells (14). Therefore, in this study, we have investigated the effects of the endogenous modulation of the Trx-TR RedOx system using sodium selenite and tested our hypothesis that PTEN activity can be modulated via the Trx system. We show that sodium selenite increases the activity of the tumor suppressor PTEN in prostate cancer cells. Interestingly, at a similar concentration, Se increases the activity of casein kinase-2 (CK2) involved in PTEN phosphorylation, thereby also regulating the tumor suppressor’s activity.

MATERIALS AND METHODS

Materials

Rabbit anti-PTEN, rabbit anti-phospho-(Ser380Thr382/383) PTEN, rabbit antiphospho-Ser473-Akt, rabbit total Akt, and rabbit PARP antibodies were purchased from Cell Signaling-Technology (Danvers, MA). Rabbit anti-phospho-Ser370-PTEN and rabbit antiphospho-Ser209-CK2 were obtained from Novus Biochemicals (Littleton, CO). Mouse anti-CK2 (clone mAb 6D5) antibody was purchased from Calbiochem (La Jolla, CA). Pleurotin (i.e., NSC131233) was recently identified as an irreversible inhibitor of TR with a K_i of 0.28 µM (19). Pleurotin and rabbit polyclonal antibodies against Trx were obtained as a gift from Dr Garth Powis (MD Anderson Cancer Center, Houston, TX). TR polyclonal antibodies were obtained from Upstate (Lake Placid, NY). Apigenin was obtained from Tocris Bioscience (Ellisville, MO). All other biochemicals were purchased from Sigma (St. Louis, MO).

Cell Culture, Sodium Selenite, and Drug Treatment

Human DU-145, LNCaP and PC-3 prostate cancer cell lines were obtained from the American Type Culture Collection (Rockville, MD). The cells were maintained in bulk culture in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Cells were passaged using 0.25% trypsin and 0.02% EDTA. The cells were confirmed to be mycoplasma free using an ELISA kit (Roche-Boehringer Mannheim, Indianapolis, IN). Sodium selenite was dissolved in distilled water at the stock concentrations of 10 mM and added every other day at the indicated concentrations to the cell culture media for 5 days. For experiments using pleurotin or apigenin, cells were preincubated for 5 days with sodium selenite followed by 1 h of drug at the concentrations indicated.

PTEN Lipid Phosphatase Activity

Lipid phosphatase activity of PTEN was measured as described by Georgescu et al. (20). Briefly, PTEN was immuno-precipitated from DU-145 cells using anti-PTEN antibody, and the lipid phosphatase activity was measured by detecting the release of phosphate from the water soluble substrate diC8-PtdIns-(3,4,5)-trisphosphate (Echelon, Salt Lake City, UT). Briefly, after immunoprecipitation, the protein A/G-agarose beads (Santa Cruz Laboratories, Santa Cruz, CA) were washed twice: once in a low-stringency buffer containing 20 mM HEPES (pH 7.7), 50 mM NaCl, 0.1 mM EDTA, and 2.5 mM MgCl2, and once in phosphate assay buffer lacking the substrate. The reaction was incubated for 40 min at 37°C and transferred to a 96-well plate. The release of phosphate from the substrate was measured in a colorimetric assay by using the Biomol Green® Reagent (Biomol, Plymouth Meeting, PA) in accordance with the instructions of the manufacturer. The absorbance at 650 nm was recorded in an ELISA plate reader. A standard curve was performed in each assay, and the amount of free phosphate was calculated from the standard curve line-fit data. Each assay was performed in triplicate, and the data are reported as nmoles of phosphate liberated/mg of total protein.

Akt and CK2 Activity and Expression in Control and Selenite-Treated DU-145 Cancer Cells

Cells were grown in 6-well plates to 75% confluency in DMEM/10% heat-inactivated FBS, 4.5 g/l glucose, 100 U/ml
penicillin, and 100 µg/ml streptomycin in a 5% CO₂ atmosphere. Following drug and/or selenite treatment, the culture media was aspirated and cells were lysed in RIPA lysis buffer made up of 0.05 M Tris, pH 7.4, 0.15 M NaCl, 1% Triton-X 100, 0.1% sodium dodecyl sulfate (SDS), and 1% sodium deoxycholate supplemented with protease and phosphatase inhibitors. Thirty micrograms of the lysates were diluted into a 4× reducing sample buffer and boiled for 5 min. Samples were then loaded on a 7.5% SDS-PAGE. Proteins were transferred to PVDF membranes, pre-incubated in blocking buffer [137 mM NaCl, 2.7 mM KCl, 897 µM CaCl₂, 491 µM MgCl₂, 3.44 mM Na₂HPO₄, 593 mM KH₂PO₄ and 5% bovine serum albumin (BSA)], and incubated with the antibodies of interest. Immunoreactive bands were detected using an anti-rabbit or anti-mouse coupled to peroxidase (Amersham, Arlington Heights, IL) and the Renaissance chemilluminescence kit (NEN, Life Science Products, Inc., Boston, MA). Bands corresponding to phospho-CK2 were quantified using Eagle Eye software (BioRad, Richmond, CA) and Kodak X-Omat Blue XB (NEN, Life Science Products). Actin or CK2 were used as respective loading controls.

TR Activity and Expression in Control and Selenite-Treated DU-145 Cells

TR activity was measured as previously described (21). Cell lysates were briefly incubated with adenosine 2′,5′ di-phosphate beads that were preswollen in 15 ml of water and rotated for an hour at 4°C. The lysates mixed with the beads were rotated for 1 h at 4°C. Lysates were washed twice in 1 ml 0.1M NaCl, 50 mM HEPES, 5mM EDTA pH 7.6, and 50 µl of 1M NaCl, 50mM HEPES and 5mM EDTA pH 7.6 was added to the beads and rotated for 1 h at 4°C. The supernatants obtained after centrifugation at 10,000 g for 5 min were used to measure TR activity. TR activity was determined spectrophotometrically at room temperature by the oxidation of NADPH at 339 nm. Samples of the supernatant were taken every 10 min for 1 h and added to 5 mM of 5,5′-dithiobisnitrobenzoic acid (DTNB), which reacts rapidly with the reduced compounds. Disappearance of DTNB was read on a spectrophotometer at 412 nm. This technique is able to measure the following reactions as illustrated below as described in Ref. 22:

1. Trx-(SH)₂ + lipoate-(S-S) → Trx-(S-S) + lipoate-(SH)₂
2. TR-(SH)₂ + Trx-(S-S) → Trx-(SH)₂ + TR-(S-S)
3. TR-(S-S) + NADPH + H⁺ → TR-(SH)₂ + NAD⁺

Apoptosis Measurement

Apoptosis was ascertained microscopically using ethidium bromide and acridine orange (27). Briefly, cells were seeded in a 30 mm plates at 1 × 10⁵ cells for 24 h until they reached confluency. They were then treated with various concentrations of sodium selenite for 5 days. Both the floating and adherent cells were collected and centrifuged. They were then washed in PBS, pH 7.0, and resuspended in 1 ml of DMEM media. To detect apoptosis, 10 µl of cells were mixed with ethidium bromide and acridine orange solution (100 µg/ml each in DMEM) and visualized for morphological changes. Acridine orange stains the nuclei green in viable cells, and the ethidium bromide is excluded. However, in apoptotic or necrotic cells, the nuclei are stained red by the ethidium bromide, and the morphology of the nucleus easily determines whether the cell is apoptotic or necrotic. A minimum count of 200 cells was counted and the percentage of apoptotic cells determined. All experiments were performed in triplicate.

Statistical Analysis

Data are presented as means ± SE. Significance was achieved with P values referred as * for P < 0.01, ** for P < 0.005, and *** for P < 0.001.

RESULTS

Sodium Selenite Increases TR Activity in Prostate Cancer Cells

TR is a known selenoprotein, and its activity can be regulated by seleno-compounds (8). We have measured TR activity in control and sodium selenite-treated prostate cancer cells. DU-145, LNCaP, and PC-3 cells lines were grown in the presence of the indicated concentration of sodium selenite (Se) for 5 days. Following this treatment, TR activity was measured as described previously (8). TR activity was increased in a dose-dependent manner in the presence of increasing concentrations of sodium selenite in DU-145 cells (Fig. 1A). In the presence of 10 µM selenite, TR was inhibited (data not shown), potentially suggesting some level of toxicity. TR was not significantly modulated in the presence of increasing concentrations of selenite in LNCaP and PC-3 cells. In fact, the level of enzyme activity was low in LNCaP as already observed by Lim and collaborators.
SELENIUM INCREASES PTEN ACTIVITY

FIG. 1. Thioredoxin reductase activity is increased by sodium selenite in DU-145 prostate cancer cells. Prostate cancer cells [DU-145, PC-3, and LNCaP] were treated for 5 days with 0.1 or 1.0 µM sodium selenite. TR activity was measured as described in Materials and Methods (Panel A). TR was increased significantly in a dose-dependent manner by sodium selenite in DU-145 cells. Bars represent means ± SE from two independent experiments performed in triplicate (n = 6). Significance was achieved: ***P < 0.001. Panel B represents the expression of TR in DU-145, PC-3, and LNCaP prostate cancer cells following 0.1 and 1.0 µM sodium selenite treatment. Note the large increase in TR protein expression in DU-145 cells as compared to LNCaP and PC-3 on 1.0 µM sodium selenite treatment. (28) who reported a TR activity of 3 times lower than in PC-3 cells. TR activity was also constitutively high in PC-3 (Fig. 1A). Figure 1B is a representative Western blot of TR protein expression in DU-145, PC-3, and LNCaP cells after sodium selenite treatment. TR protein expression was considerably increased in the presence of increasing concentration of selenite in DU-145 cells. However, LNCaP cells did not express detectable levels of TR, and sodium selenite treatment had no significant effect on TR expression and activity (Figs. 1A and 1B). In PC-3 cells, although a marked increase in the expression of TR was observed following 1 µM treatment, the measure of TR activity did not correlate with this increase. These results may reflect other RedOx systems being measured using this technique. Nonetheless, we show TR expression and activity was significantly increased by sodium selenite in DU-145 cells. The increase in TR activity has been shown to occur over a range of Se concentrations from <0.01 to 10 µM (29), which encompasses the range of Se concentrations found in human serum (between 1 and 5 µM) (30).

We next measured GSH peroxidase activity in these same cells. GSH peroxidase activity was increased by a factor of 8 in PC-3 on increasing concentrations of sodium selenite (Fig. 2). This observation could explain, at least in part, the high TR activity measured in Fig. 1A. In DU-145 and LNCaP cells, GSH peroxidase was slightly increased by sodium selenite in a dose-dependent manner. However, this increase was considered as negligible when compared to the increase observed in PC-3 cells. In all the 3 cell lines tested, higher concentrations of sodium selenite (10 µM) were shown also to become toxic (data not shown). In conclusion, we showed that sodium selenite increases TR in DU-145 cells, and that increase is not due to GST peroxidase activity.

Sodium Selenite Increases the RedOx Rate of Trx in DU-145 Prostate Cancer Cells Independently of GSH

We have shown previously that the covalent interaction between Trx and PTEN occurs via disulfur bridges between Cys-32 of Trx and Cys-212 of the C2 domain of PTEN (14). Because TR activity was increased by sodium selenite, the bioreduction capacity of the Trx system was determined using lipoate as a substrate in DU-145 cells (Fig. 3A). The rate of lipoate bioreduction is known to be primarily coupled to Trx as described previously (23–26). As observed with TR activity, increasing concentrations of sodium selenite increases the bioreduction rate of lipoate in a dose-dependent manner in DU-145 cells (Fig. 3A). Incubation of DU-145 cells with 0.1 or 1.0 µM sodium selenite increased the rate of lipoate bioreduction by 36% and
FIG. 3. Effect of sodium selenite on Trx and GSH bioreduction capacity. DU-145 cells were treated with various concentrations of sodium selenite for 5 days at the indicated concentrations. Panel A: DU-145 cells were treated with sodium selenite for 5 days and BSO at 1 mM for 1 h prior to the bioreduction assay. Cells were incubated with buffer containing 5 mM glucose plus vehicle or 5 mM oxidized lipoate. The rate of Trx bioreduction was determined using 6 measurements over a 1-h period in duplicate treatment samples. Note that Trx’s bioreduction potential increased significantly on sodium selenite treatment. Bars represent means ± SE from three independent experiments performed in triplicate. Significance was achieved: ***P < 0.001 when compared to respective vehicles; #P < 0.01 when compared to lipoate reduction in control. Panel B: DU-145 cells were treated with sodium selenite for 5 days, and then cells were incubated with buffer containing 5 mM glucose plus vehicle or 5 mM HEDS. Note that there was no effect of selenite on GSH bioreduction. Bars represent means ± SE from 3 independent experiments performed in duplicate. BSO, buthionine sulphoximine.

Sodium Selenite Increases PTEN Lipid Activity in DU-145 Cells

We have recently reported that Trx binds to PTEN in a RedOx-dependent manner and inhibits its lipid phosphatase activity (14,15). Moreover, TR is a selenium-dependent enzyme, and increasing concentrations of sodium selenite increase TR expression and activity (Fig. 1 and Ref. 8). Consequently, we hypothesized that by increasing TR activity via increasing amounts of sodium selenite, the RedOx rate of Trx increases in the cells. TR would then not be able to interact with PTEN and thus would allow PTEN to be active. To test this hypothesis, DU-145 cells were treated with increasing amounts of sodium selenite, and PTEN lipid phosphatase activity was measured as previously described (20). Figure 4A summarizes the effects of sodium selenite in DU-145 cells on PTEN lipid phosphatase activity using phosphatidyl-myoinositol(3,4,5)-trisphosphate as substrate. PTEN activity from these cells was significantly increased by sodium selenite in a dose-dependent manner. There was no change in PTEN protein expression in DU-145 cells in the presence of selenite as compared to control cells (Fig. 4A, insert).

To test whether this interaction is also dependent of TR activity, we used pleurotin (i.e., NSC131233; Ref. 19), a known inhibitor for TR, and measured PTEN lipid phosphatase activity in DU-145 cells (Fig. 4B). Cells were pretreated with sodium selenite (1 µM), pleurotin (5 µM), or the combination, and PTEN lipid phosphatase was measured in DU-145 cells. As shown in Fig. 4A, sodium selenite increased PTEN activity. Pleurotin decreased PTEN activity, and the combination was able to restore PTEN activity to its basal activity as compared to control nontreated cells. Therefore, sodium selenite regulates PTEN activity, which may be in part via the activation of the Trx-TR system in DU-145 prostate cancer cells.

Sodium Selenite Inhibits Akt Phosphorylation and Induces Apoptosis in Prostate Cancer Cells

We have shown that PTEN lipid phosphatase is activated following sodium selenite treatment in DU-145 prostate cancer cells. Activation of PTEN has been correlated with a decrease in Akt activation in cells and an increase in apoptosis (31). To correlate the activity of PTEN with that of Akt, we have treated DU-145 cells with sodium selenite for 5 days and measured sodium-selenite-induced apoptosis as well as the phosphorylation status of Akt. The results are summarized in Fig. 5. A
FIG. 4. PTEN lipid phosphatase is increased by sodium selenite via the Trx-TR system. Panel A represents PTEN lipid phosphatase activity as measured by the release of nmoles of phosphate from the substrate PtdIns-3,4,5-P3 as described in Materials and Methods section. Note that increasing concentrations of sodium selenite stimulates PTEN lipid phosphatase activity in DU-145 cells. Inset shows the total PTEN protein expression in the corresponding samples as compared to internal control, β-actin. Panel B represents PTEN activity following 1 µM sodium selenite, 5 µM pleurotin (an inhibitor of TR), or the combination treatment. The combination treatment restores PTEN activity back to basal activity as compared to that in control cells. Bars represent means ± SE from three independent experiments performed in triplicate. Significance was achieved: ***P < 0.001.

FIG. 5. Sodium selenite inhibits Akt activation and induces apoptosis and PARP cleavage in DU-145 prostate cancer cells. The insert of Panel A represents a typical Western blot for the inhibition of Akt phosphorylation by increasing concentrations of sodium selenite (Se) in DU-145 cells. Briefly, cells were lysed, and phosphorylated Akt was detected using specific antiphospho-Ser473-Akt. Akt phosphorylation was decreased in the presence of increasing concentration of sodium selenite in DU-145 cells, correlating with the increase in PTEN lipid phosphatase activity. The graph in Panel A represents the induction of apoptosis in DU-145 cells by selenite as measured by the morphological assay described in Materials and Methods. Bars represent means ± SE from two independent experiments performed in triplicate. Significance was achieved: **P < 0.01. Panel B represents a typical Western blot for the cleavage of PARP by increasing concentrations of sodium selenite in DU-145 cells. Actin was used as a loading control. Note the lower band appearing in cells treated with 5 µM selenite, which corresponds to cleaved PARP and induction of apoptosis (Panel A).

statistically significant increase in apoptosis was observed following 1 µM and 5 µM sodium selenite treatments in DU-145 cells (Fig. 5, Panel A). As already shown by Menter et al. (32), apoptosis was also confirmed by monitoring PARP cleavage following 5 µM sodium selenite treatment in these cells (Fig. 5, Panel B). A dose-dependent decrease in Akt phosphorylation on Ser473 was also observed in sodium-selenite-treated DU-145 cells (Fig. 5, insert, Panel A). These observations are in agreement with the increase in PTEN activity, correlating with a decrease in Akt phosphorylation, leading to the induction of apoptosis in DU145 cells. In conclusion, we showed that sodium selenite treatment caused a decrease in Akt phosphorylation and a significant increase in apoptosis in DU-145 cells.

Sodium Selenite Modulates PTEN Activity Also Via Casein Kinase 2 in DU-145 Prostate Cancer Cells

PTEN activity has been recently shown to be strongly regulated by its phosphorylation status (16,17). Because sodium selenite is also known to affect the expression as well as the activity of several enzymes, we have also tested the effects of...
FIG. 6. Sodium selenite modulated PTEN phosphorylation in DU-145 cells. DU-145 cells were treated with increasing concentrations of sodium selenite for 5 days. Cells were lysed, and samples were probed for PTEN phosphorylation using specific phospho-antibodies. Panel A represents a typical Western blot for PTEN phosphorylation on residues Ser\(^{380/382/383}\), PTEN phosphorylation on Ser\(^{380}\) and on Ser\(^{370}\) as compared to loading control with β-actin. Note the decrease in PTEN phosphorylation with 5 \(\mu\)M of sodium selenite on Ser\(^{380/382/383}\) and a slight increase in PTEN phosphorylation on Ser\(^{370}\). Panel B represents the expression and the phosphorylation status of CK2 involved in the phosphorylation of PTEN following increasing concentrations of sodium selenite in DU-145, LNCaP and PC-3 prostate cancer cells. Cells were treated with 1 \(\mu\)M of Se. Note the high levels of CK2 and phospho-(Ser\(^{209}\))-CK2 in DU-145 cells as compared to the other cell lines.

sodium selenite on PTEN phosphorylation status in DU-145 cells using specific phosphoantibodies as well as the expression of the kinases involved in the phosphorylation of PTEN. Phosphorylation on Ser\(^{380/382/383}\) was slightly decreased in a dose-dependent manner, but phospho-Ser\(^{380}\)-PTEN remained unchanged in the presence of increasing concentrations of selenite (Fig. 6A). Phospho-Ser\(^{370}\)-PTEN appeared to increase slightly on selenium treatment. Therefore, we hypothesized that the activity of the kinases involved in the phosphorylation and regulation of PTEN activity may be also affected by sodium selenite.

More specifically, we investigated the expression levels as well as the activity of CK2, a kinase known to phosphorylate PTEN (33). DU-145 cells expressed high levels of CK2 as compared to LNCaP and PC-3 cells (Fig. 6B). Moreover, the addition of 1 \(\mu\)M of Se increased pSer\(^{209}\)-CK2 levels only in DU-145 cells and reduced it in the other cell lines. The activity of CK2, as measured by the ratio of phospho-Ser\(^{209}\)-CK2 over total CK2, was significantly increased in DU-145 following 1 \(\mu\)M of selenite treatment (Fig. 7A). Apigenin, a known inhibitor of CK2 (34), was also shown to reduce phospho-Ser\(^{209}\)-CK2 and confirmed its inhibitory effects on the kinase (Fig. 7B). Apigenin-induced inhibition could partially be rescued by 1 \(\mu\)M of selenite. CK2 is one of the kinases that phosphorylates PTEN and stabilizes the protein in an active form (33). Thus, to test the hypothesis that by increasing the activity of
CK2 sodium selenite could also modulate the activity of PTEN, DU-145 cells were pretreated with Se and then incubated with apigenin or vehicle control. Figure 7, Panel C, represents a representative Western blot correlating the phosphorylation status of PTEN, AKT, and CK2. We show that phospho-Ser209-AKT2 remains high in presence of 1 μM selenite and that consequently, phospho-Ser370-PTEN is also high correlating with a low phospho-Ser473-AKT. Apigenin decreased CK2 phosphorylation, which in turn also decreased Ser380/Thr382/383-PTEN phosphorylation as well as Ser473-Akt. Although these phosphorylation sites on PTEN have been suggested to act to facilitate PTEN phosphorylation on other residues but do not affect the lipid phosphatase activity, they may play a role in selenite-mediated effects on the PTEN/Akt pathway in prostate cancer cells.

DISCUSSION

Epidemiological studies have shown that there is a consistent trend for populations residing in geographic areas that have low selenium levels in the soil to have a high mortality from cancer. Other studies have show a lower risk for prostate cancer in individuals with selenium supplementation (35), and higher serum selenium concentrations correlates with a moderately reduced risk of prostate cancer (36). These cancers include cancers of the bladder, pancreas, thyroid, stomach, lung, esophagus, melanoma, head and neck tumors, and brain tumors. More specifically, several studies have suggested a protective role of selenium compounds against several cancers including prostate cancer (reviewed in Ref. 37). In an attempt to better understand the protective effects of Se on prostate cancer cells, we have studied the effects of sodium selenite on the regulation of the cell survival pathway, phosphatidylinositol-3 kinase/Akt/PTEN. Previously, we have shown in cell culture systems that human Trx binds in a RedOx-dependent manner to PTEN and inhibits its PtdIns-3-phosphatase activity, resulting in increased Akt activation (14). Molecular docking and site-specific mutation studies have shown that the binding of hTrx to PTEN occurs through a disulfide bond between the active site Cys32 of hTrx and Cys218 of the C2 domain of PTEN, leading to steric interference by bound Trx of the catalytic site of PTEN and of the C2 lipid membrane-binding domain (14). Se is an essential element in RedOx pathways and acts as an effective oxidant of bioreduced Trx and bioreduced TR, which diminishes the Trx-TR pool. This important role of sodium selenite may explain its inhibitory influence on cell growth and cancer progression (32). Consequently, we have hypothesized that by modulating the Trx-TR RedOx system endogenously with sodium selenite, PTEN activity can be regulated in prostate cancer cells. We show that sodium selenite decreases Akt phosphorylation by increasing PTEN lipid phosphatase activity in DU-145 cells. Consistent with others, it has been shown that sodium selenite induces a dose-dependent growth inhibition of prostate cancer cells such as DU-145, PC-3, and LNCaP (32) and an induction of apoptosis in selenite-treated prostate cancer cells (32). Our observations are in agreement with these studies and confirm the inhibitory effects of sodium selenite on Akt phosphorylation, leading to the increase in apoptosis. However, we show here that it is by releasing PTEN from the inhibitory binding of Trx that Se treatment leads to a decrease in Akt phosphorylation and consequently to apoptosis in DU-145 cells.

In this study, we also showed that selenite increased the activity of a kinase involved in PTEN phosphorylation and thereby regulated the tumor suppressor’s activity in these cells. In the DU-145 prostate cancer cells, which express an active PTEN (38), we expected a bigger effect on Akt; however, Akt phosphorylation was only slightly decreased in the presence of sodium selenite. The reason for these observations may reflect the dual role of CK2. CK2 is a ubiquitous serine/threonine kinase for which regulation and function is not well understood yet (39). Originally, CK2 was defined as a constitutively active protein kinase, although recently several reports have suggested that CK2 acts as a regulated kinase participating in signal transduction. Indeed, CK2 was recently identified as the kinase that phosphorylates the C-terminus of PTEN on residues Ser385 and Ser370 (33,40,41). CK2 has been demonstrated to also phosphorylate PTEN on Ser380 and thereby affects its stability (33). The phosphorylation by CK2 hinders the cleavage of PTEN by caspases. On the other hand, CK2 also phosphorylates at Ser129 of Akt and upregulates Akt activity in Jurkat cells (42). In this study, we showed that CK2 activity is increased upon selenite treatment. The increase in phosphorylation of CK2 may translate itself in an increase in Ser129 phosphorylation of Akt, leading to an increase in Akt activity and thereby counterbalancing the effects of selenite on PTEN activity via the Trx-TR system. Interestingly, using apigenin, an inhibitor for CK2, we showed that the decrease in Akt phosphorylation due to the increase in PTEN activity can be enhanced. This suggests that upregulation of CK2 activity with selenite may contribute to the observed decrease in the effects of selenite on Akt. Therefore, although we observed an increase in phosphorylation status of CK2, overall the effects of sodium selenite are counteracted by the fact that CK2 directly phosphorylates Akt to increase its activity and its phosphorylation status at Ser473.

Sodium selenite may modulate the activity of protein kinases and other enzymes through phosphorylation-independent mechanisms such as RedOx modification. In this study, we have shown that sodium selenite increased CK2 activity in prostate cancer cells. The regulation of this enzyme is then affecting PTEN activity because it has been recently found to phosphorylate PTEN and influence the stability and the activity of the tumor suppressor. Interestingly, recent studies that have used apigenin have shown that the downregulation of CK2 in prostate cancer cells promotes apoptosis (43). These observations correlate well with our study presented in this article. Finally, although apigenin’s mechanism of action remains to be clearly established and probably extends beyond the inhibition of CK2,
the novel finding that Se increases CK2 activity, which in turn can affect PTEN activity, is of interest for the treatment of prostate cancer.

In conclusion, we have demonstrated that the regulation of PTEN activity may be achieved at least in part via the modulation of the Trx-TR system by selenite as well as the RedOx properties of the kinases involved in PTEN phosphorylation. These results may explain, at least in part, and contribute to understanding the chemopreventive effects of sodium selenite against prostate cancers. However, they also suggest the importance of PTEN status (expression as well as phosphorylation) in predicting the possible therapeutic effects of sodium selenite.

REFERENCES


